Suspension is lifted
Lysaker, 2 May 2025
Yesterday's suspension from the live trading on Nasdaq Copenhagen is now liftet on behalf of the below funds, and the share classes will resume trading today on 2 May.
Regards
Storebrand Asset Management AS
Contacts:
Henrik Budde Gantzel, Director, henrik.budde.gantzel@storebrand.no
Frode Aasen, Product Manager, fdc@storebrand.com
Fund name and share class
Symbol
ISIN
SKAGEN Focus A
SKIFOA
NO0010735129
SKAGEN Global A
SKIGLO
NO0008004009
SKAGEN Kon-Tiki A
SKIKON
NO0010140502
SKAGEN m2 A
SKIM2
NO0010657356
SKAGEN Vekst A
SKIVEK
NO0008000445
Storebrand Indeks – Alle Markeder A5
STIIAM
NO0010841588
Storebrand Indeks – Nye Markeder A5
STIINM
NO0010841570
Storebrand Global Plus A5
STIGEP
NO0010841604
Storebrand Global Solutions A5
STIGS
NO0010841612
Storebrand Global Multifactor A5
STIGM
NO0010841596
Storebrand is Norway's largest private asset manager with an AuM of around DKK 900 billion, and a leading Nordic provider of sustainable pensions and savings. The company has been a global pioneer in ESG investing for over 30 years, offering broad and scalable solutions for both institutional and private investors in the Nordic region and other European countries. In Denmark, Storebrand delivers sustainable investment solutions and client value through a multi-boutique platform, with the brands Storebrand Funds, SKAGEN Funds, Cubera Private Equity, Capital Investment and a majority ownership of AIP.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 days ago
- Business Insider
Genmab price target lowered to DKK 1,500 from DKK 1,700 at JPMorgan
JPMorgan lowered the firm's price target on Genmab (GMAB) to DKK 1,500 from DKK 1,700 and keeps a Neutral rating on the shares. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
2 days ago
- Yahoo
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ('Zealand Pharma') (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma's incentive scheme. Each warrant gives the owner the right to subscribe for one newly issued Zealand Pharma share at a prespecified exercise price within the specific predefined time periods before expiration in the warrant programs. For a more detailed description of Zealand Pharma's warrant programs, see the company's Articles of Association, which are available on the website: The exercise price was DKK 224.40 per share for 4,163 of new shares and DKK 90.70 per share for 288,345 of new shares. The total proceeds to Zealand Pharma from the capital increase amount to DKK 27,087,068.70. The new shares give rights to dividends and other rights from the time of the respective warrant holder's exercise notice. Each new share carries one vote at Zealand Pharma's general meetings. Zealand Pharma has only one class of shares. The new shares will be admitted to trading on Nasdaq Copenhagen after the capital increase has been registered with the Danish Business Authority. Following registration of the capital increase with the Danish Business Authority, the share capital of Zealand Pharma will be nominally DKK 71,343,804 divided into 71,343,804 shares with a nominal value of DKK 1 each and corresponding to a total of 71,343,804 votes. A full copy of the new and amended Articles of Association can be found at once registered with the Danish Business Authority. # # # About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactsAdam Lange (Investors)Vice President, Investor RelationsZealand PharmaEmail: alange@ Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@ Anna Krassowska, PhD (Investors and Media)Vice President, Investor Relations & Corporate CommunicationsZealand Pharmaakrassowska@ in to access your portfolio
Yahoo
3 days ago
- Yahoo
Updated financial Calendar for 2025
Company announcement no. 21In continuation of Nykredit takeover of Spar Nord Bank (company announcement no. 15/2025) the Bank's financial calendar for 2025 is updated. Spar Nord Bank now expects to announce the financial statements on the following dates: Date Event 14th August 2025 Semi-Annual Report 30th October 2025 Quarterly Report – Q3Rune Brandt BørglumCFO Attachment Nr. 21 - Updated financial Calendar for 2025 - UKSign in to access your portfolio
